Search

Your search keyword '"Hematology and Oncology"' showing total 45,054 results
Start Over Author "Hematology and Oncology"
45,054 results on '"Hematology and Oncology"'

2. Master Framework For Relapse or Refractory Acute Myeloid Leukemia (IMPACT STREAM)

Author

Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, and Time.Lex

Published
2024

4. International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Author

Australian & New Zealand Children's Haematology/Oncology Group, St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria), European Organisation for Research and Treatment of Cancer - EORTC, University Hospital Motol (Co-Sponsor Czech Republic), Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark), Turku University Central Hospital (co-sponsor, Finland), Centre Hospitalier Universitaire de Nice, Our Lady's Chilrden's Hospital (Co-Sponsor Ireland), Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel), Ospedale Pediatrico Bambino (co-sponsor, Italy), Prinses Máxima Centrum (Co-Sponsor Netherlands), Oslo University Hospital (co-sponsor, Norway), Medical University of Wroclaw (Co-Sponsor Poland), Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal), Karolinska University Hospital Stockholm (co-sponsor, Sweden), Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain), University Children's Hospital, Zurich, Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK), and PD Dr. Arend von Stackelberg, Prinicipal Investigator

Published
2024

5. International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

Author

Australian & New Zealand Children's Haematology/Oncology Group, St. Anna Kinderkrebsforschung (Co-Sponsor Austria), European Organisation for Research and Treatment of Cancer - EORTC, University Hospital Motol (Co-Sponsor Czech Republic), Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen), Turku University (Co-Sponsor Finland), Centre Hospitalier Universitaire de Nice, Our Lady's Chilrden's Hospital (Co-Sponsor Ireland), Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel), Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy), National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan), Prinses Máxima Centrum (Co-Sponsor Netherlands), Oslo University Hospital (Co-Sponsor Oslo), Medical University of Wroclaw (Co-Sponsor Poland), Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa), Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain), University Children's Hospital, Zurich, Central Manchester University (Co-Sponsor United Kingdom), and PD Dr. Arend von Stackelberg, PD Dr. med. Arend von Stackelberg

Published
2024

6. Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia

Author

Danish Child Cancer Foundation, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital, Royal Children's Hospital, St. Jude Children's Research Hospital, Princess Maxima Center for Pediatric Oncology, Nordic Society for Pediatric Hematology and Oncology, Medical University of Lodz, and Kjeld Schmiegelow, Professor, DMSc

Published
2023

8. HCT Versus CT in Elderly AML

Author

Acute Leukemia French Association, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, European Organisation for Research and Treatment of Cancer - EORTC, French Innovative Leukemia Organisation, HOVON - Dutch Haemato-Oncology Association, East German Study Group of Hematology and Oncology (OSHO), and Swiss Group for Clinical Cancer Research

Published
2021

9. Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Author

Xinqiao Hospital of Chongqing, The First Affiliated Hospital of Anhui Medical University, Harbin Hematology and Oncology Institute, The Affiliated Zhongshan Hospital of Dalian University, Qilu Hospital of Shandong University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Huashan Hospital, and Zhao Weili, First Deputy Director, Hematology Department

Published
2021

11. Chilean Gastric Cancer Task Force (FORCE 1) (FORCE-1)

Author

Center of Excellence of Precision Medicine (CEMP), Advanced Center for Chronic Diseases (ACCDiS), Millennium Institute on Immunology and Immunotherapy, Center UC for Investigation in Oncology (CITO), Centre of Clinical Research, Health Technology Assessment Unit, National Scientific and Technical Research Council (CONICET), Argentina, Grupo Oncologico Cooperativo del Sur (GOCS), Argentina, Hospital Universitario central de Asurias, Oviedo, España, Hospital Morales Meseger, Murcia, España, Centro de Cancer. Pontificia Universidad Católica de Chile, and Hematology and Oncology Department

Published
2019

14. ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Author

Shandong University of Traditional Chinese Medicine, Jining Medical University, Weifang Medical University, Guangzhou First People's Hospital, Harbin Hematology and Oncology Institute, Jining First People's Hospital, JIANGXI Provincal People's Hospital, Jinhua Central Hospital, Linyi People's Hospital, Shandong Cord Blood Bank, Qingdao Hiser Medical Group, Qingdao University, Taian City Central Hospital, Yantai Yuhuangding Hospital, Yishui Central Hospital of LINYI, Institute of Hematology & Blood Diseases Hospital, China, Shengjing Hospital, and Fang Zhou, Principal Investigator

Published
2017

15. Characteristics, management, and outcome of pediatric patients with post‐transplant lymphoproliferative disease—A 20 years' experience from Austria

Author

Anna Füreder, Gabriele Kropshofer, Martin Benesch, Michael Dworzak, Sabine Greil, Wolf‐Dietrich Huber, Holger Hubmann, Anita Lawitschka, Georg Mann, Ina Michel‐Behnke, Thomas Müller‐Sacherer, Herbert Pichler, Ingrid Simonitsch‐Klupp, Wolfgang Schwinger, Zsolt Szepfalusi, Roman Crazzolara, Andishe Attarbaschi, and Austrian Society of Pediatric Hematology and Oncology

Subjects
hematopoietic stem cell transplantation, outcome, post‐transplant lymphoproliferative disease, solid organ transplantation, treatment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Management of pediatric post‐transplantation lymphoproliferative disorder (PTLD) after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) is challenging. Aim This study of 34 PTLD patients up to 19‐years old diagnosed in Austria from 2000 to 2018 aimed at assessing initial characteristics, therapy, response, and outcome as well as prognostic markers of this rare pediatric disease. Methods and results A retrospective data analysis was performed. Types of allografts were kidney (n = 12), liver (n = 7), heart (n = 5), hematopoietic stem cells (n = 4), lungs (n = 2), multi‐visceral (n = 2), small intestine (n = 1), and vessels (n = 1). Eighteen/34 were classified as monomorphic PTLD, with DLBCL accounting for 15 cases. Polymorphic disease occurred in nine, and non‐destructive lesions in six cases. One patient had a non‐classifiable PTLD. Thirteen/34 patients are surviving event‐free in first remission (non‐destructive, n = 4/6; polymorphic, n = 4/9; monomorphic, n = 6/18). Fourteen/34 patients lacked complete response to first‐line therapy, of whom seven died. Four/34 patients relapsed, of whom two died. In 3/34 patients, death occurred as a first event. The 5‐year overall and event‐free survival rates were 64% ± 9% and 35% ± 9% for the whole cohort. Among all parameters analyzed, only malignant disease as the indication for transplantation had a significantly poor influence on survival. Conclusions This study shows PTLD still to be a major cause of mortality following SOT or HSCT in children. A continued understanding of the molecular biology of the disease shall allow to decrease treatment intensity for lower risk patients and to identify patients who may benefit from newer therapy approaches to improve outcome and decrease morbidity.

Published
2021
Full Text
View/download PDF

17. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation

Author

Schmidt, Volker, Niederwieser, Dietger, Schenk, Thomas, Behre, Gerhard, Klink, Anne, Pfrepper, Christian, Hinke, Axel, Beelen, Dietrich W., Junghanss, Christian, Uharek, Lutz, Krüger, William H., Hochhaus, Andreas, Sayer, Herbert G., and for the East German Study Group for Hematology and Oncology (OSHO)

Published
2018
Full Text
View/download PDF

18. Second Malignant Neoplasms After Childhood ALL Therapy (PdL-SMN1)

Author

Nordic Society for Pediatric Hematology and Oncology, European Organisation for Research and Treatment of Cancer - EORTC, Dana-Farber Cancer Institute, ALL-BFM Study Group, Dutch Childhood Oncology Group, St. Jude Children's Research Hospital, United Kingdom Children's Cancer Study Group, and Kjeld Schmiegelow, Professor

Published
2012

22. Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Author

Zhejiang University, Peking University People's Hospital, Air Force Military Medical University, China, Xiangya Hospital of Central South University, Institute of Hematology & Blood Diseases Hospital, China, Union hospital of Fujian Medical University, Harbin Hematology and Oncology Institute, First Affiliated Hospital, Sun Yat-Sen University, Beijing Jishuitan Hospital, and Hou Jian/Director of department of hematology

Published
2010

27. Results with Randomized BFM Adopted Studies for ALL Therapy in Childhood in East German Countries

Author

The former Working Group Pediatric Hematology and Oncology, Zintl, F., Malke, H., Reimann, M., Domula, M., Dörffel, W., Eggers, G., Exadaktylos, P., Hilgenfeld, E., Kotte, W., Krause, I., Kunert, W., Mittler, U., Möbius, D., Reddemann, H., Weinmann, G., Weißbach, G., Büchner, T., editor, Hiddemann, W., editor, Wörmann, B., editor, Schellong, G., editor, and Ritter, J., editor

Published
1994
Full Text
View/download PDF

28. Protocol-RNA-ISH v1

Author

Klaus Hirschbühl (Hematology and Oncology Medical Faculty Univers

Abstract

Protocol-RNA-ISH to the paper: Viral mapping in COVID-19 deceased in the Augsburg autopsy series of the first wave: a multiorgan and multimethodological approach Full organ mapping of patients with COVID-19: an autopsy study

Published
2021

29. Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma

Author

Peck-Radosavljevic, Markus, Sieghart, Wolfgang, Kölblinger, Claus, Reiter, Markus, Schindl, Martin, Ulbrich, Gregor, Steininger, Rudolf, Müller, Christian, Stauber, Rudolf, Schöniger-Hekele, Maximilian, Gschwendtner, Manfred, Plank, Christina, Funovics, Martin, Graziadei, Ivo, Lammer, Johannes, Gruenberger, Thomas, Gastl, Günther, Karnel, Franz, the Austrian Association of Gastroenterology,Hepatology (ÖGGH), the Austrian Society of Interventional Radiology (ÖGIR), the Austrian Society of Hematology and Oncology (ÖGHO), and the Austrian Society for Surgical Oncology (ASSO)

Published
2012
Full Text
View/download PDF

31. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

Author

Nishimori, Hisakazu, Matsuo, Keitaro, Maeda, Yoshinobu, Nawa, Yuichiro, Sunami, Kazutaka, Togitani, Kazuto, Takimoto, Hidetaka, Hiramatsu, Yasushi, Kiguchi, Toru, Yano, Tomofumi, Yamane, Hiromichi, Tabayashi, Takayuki, Takeuchi, Makoto, Makita, Masanori, Sezaki, Nobuo, Yamasuji, Yoshiko, Sugiyama, Haruko, Tabuchi, Takahiro, Kataoka, Itaru, Fujii, Nobuharu, Ishimaru, Fumihiko, Shinagawa, Katsuji, Ikeda, Kazuma, Hara, Masamichi, Yoshino, Tadashi, Tanimoto, Mitsune, and for the West-Japan Hematology and Oncology Group (West-JHOG)

Published
2009
Full Text
View/download PDF

32. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

Author

Hiramatsu, Yasushi, Maeda, Yoshinobu, Fujii, Nobuharu, Saito, Takashi, Nawa, Yuichiro, Hara, Masamichi, Yano, Tomofumi, Asakura, Shoji, Sunami, Kazutaka, Tabayashi, Takayuki, Miyata, Akira, Matsuoka, Ken-ichi, Shinagawa, Katsuji, Ikeda, Kazuma, Matsuo, Keitaro, Tanimoto, Mitsune, and for the West-Japan Hematology and Oncology Group (West-JHOG)

Published
2008
Full Text
View/download PDF

33. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Author

Herold, M., Schulze, A., Niederwieser, D., Franke, A., Fricke, H. J., Richter, P., Freund, M., Ismer, B., Dachselt, K., Boewer, C., Schirmer, V., Weniger, J., Pasold, R., Winkelmann, C., Klinkenstein, C., Schulze, M., Arzberger, H., Bremer, K., Hahnfeld, S., Schwarzer, A., Müller, C., Müller, Chr., and for the East German Study Group Hematology and Oncology (OSHO)

Published
2006
Full Text
View/download PDF

34. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.

Author

Francois P Duhoux, Geneviève Ameye, Virginie Lambot, Christian Herens, Frédéric Lambert, Sophie Raynaud, Iwona Wlodarska, Lucienne Michaux, Catherine Roche-Lestienne, Elise Labis, Sylvie Taviaux, Elise Chapiro, Florence Nguyen-Khac, Stéphanie Struski, Sophie Dobbelstein, Nicole Dastugue, Eric Lippert, Frank Speleman, Nadine Van Roy, An De Weer, Katrina Rack, Pascaline Talmant, Steven Richebourg, Francine Mugneret, Isabelle Tigaud, Marie-Joëlle Mozziconacci, Sophy Laibe, Nathalie Nadal, Christine Terré, Jeanne-Marie Libouton, Anabelle Decottignies, Miikka Vikkula, Hélène A Poirel, Groupe Francophone de Cytogénétique Hématologique (GFCH), and Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO)

Subjects
Medicine, Science
Abstract

Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mainly observed in myeloid disorders; and unbalanced non-telomeric rearrangements (N = 39), mainly observed in lymphoid proliferations and frequently associated with a highly complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36 were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas [follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or result from chromosomal instability during oncogenesis.

Published
2011
Full Text
View/download PDF

35. Use of murine L1210 and P388 lymphocytic leukemia cells in cytotoxic studies of flavonoids

Author

Sak, Katrin; Department of Hematology and Oncology, University of Tartu, Everaus, Hele; Department of Hematology and Oncology, University of Tartu, Tartu, Estonia, Sak, Katrin; Department of Hematology and Oncology, University of Tartu, and Everaus, Hele; Department of Hematology and Oncology, University of Tartu, Tartu, Estonia

Abstract

In studies of antileukemic properties of flavonoids two murine cellular systems (L1210 and P388) are widely used beside the various established human leukemia lines. Differently from conventional clinically used chemotherapeutics, P388 cells reveal somewhat lower susceptibility towards plant polyphenolic agents than L1210 cells. Moreover, based on the cytotoxic analysis of different flavonoids, we provide some novel evidence of Burkitt`s lymphoma as a human equivalent of L1210 mouse model, enabling thus the use of L1210 murine model in development of novel antilymphoma drugs proceeding from natural polyphenols. At that, structurally different flavones can be considered as potential lead compounds; however, the most potent flavonoid described so far in B-cell lymphoma cells is the rotenoid deguelin, certainly requiring further in vitro and in vivo investigation.

Published
2015

36. Neonatal Alloimmune Thrombocytopenia

Author

J, Roganović, Department of Pediatrics, Division of Hematology and Oncology, University Hospital Centre Rijeka, Croatia., I, Kranjcec, and Division of Hematology and Oncology, Children's Hospital Zagreb, Zagreb, Croatia

Subjects
thrombocytopenia, newborns, thrombocytopenia, neonatal alloimmune, antigens, human platelets, business.industry, Neonatal alloimmune thrombocytopenia, Immunology, medicine, medicine.disease, business
Abstract

Neonatal alloimmune thrombocytopenia is the most common cause of immune-mediated thrombocytopenia in the new born period. The disorder results from placental transfer of maternal alloantibodies directed against paternally inherited antigens carried on fetal platelets. While most cases are mild, some neonates have very low platelet counts associated with serious bleeding in hours to days following birth. The treatment for severely affected neonate is typically transfusion of compatible random donor platelets in addition to intravenous immunoglobulins. The diagnosis is confirmed by genotyping of parental platelet antigens and serological testing for maternal serum antibodies. We present a newborn with early onset symptomatic thrombocytopenia, in whom early clinical recognition and prompt therapeutic intervention resulted in the complete recovery. The importance of correct diagnosis for future pregnancies is emphasized.

Published
2015

37. Management of children and adolescents with gray zone lymphoma: A case series.

Author

Perwein, Thomas, Lackner, Herwig, Ebetsberger‐Dachs, Georg, Beham‐Schmid, Christine, Zach, Klara, Tamesberger, Melanie, Simonitsch‐Klupp, Ingrid, Lüftinger, Roswitha, Dworzak, Michael, Mann, Georg, Benesch, Martin, Attarbaschi, Andishe, Ebetsberger-Dachs, Georg, Beham-Schmid, Christine, Simonitsch-Klupp, Ingrid, and Austrian Society of Pediatric Hematology and Oncology and the Austrian Berlin-Frankfurt-Münster (BFM) Study Group

Published
2020
Full Text
View/download PDF

38. A supposed mechanism of synergistic action of catechol-containing natural polyphenols

Author

None declare, Sak, Katrin; Department of Hematology and Oncology, University of Tartu, None declare, and Sak, Katrin; Department of Hematology and Oncology, University of Tartu

Abstract

Over the past decades, accumulated evidences have been published about different synergistic biological activities between natural dietary polyphenols. Although these effects could be physiologically important in chemoprevention, cardioprotection and neuroprotection, but probably also in treatment of serious chronic diseases, such as cancer, the exact mechanisms behind this potentiation have still remained largely unknown. In this article, supposition about the involvement of phase II metabolic enzyme, catechol-O-methyltransferase (COMT), in the synergistic action of catechol-containing polyphenols is proposed. Serving as substrates, these compounds can also behave as COMT inhibitors suppressing the O-methylation of the other catechol-containing component in the combined mixture. At that, negative feedback by the increased amount of S-adenosyl-L-homocysteine generated from the methyl-group donor S-adenosyl-L-methionine during the enzymatic conversion can play an important role. Presuming that O-methylated conjugates are in general biologically less active than their unmetabolised counterparts, cotreatment of cells with combination of two catecholic natural agents can lead to a superior effect as compared to the administration of either compound alone. This mechanism can provide an explanation to the beneficial synergistic effects described for green tea extracts in chemoprevention or red wine consumption in protection of cardiovascular system in comparison with their single components tested separately. However, as currently only little is known about the possible biological activities of O-methylated conjugates of dietary polyphenolic phytochemicals, their nature and effects definitely need to be further studied. These results could prove (or disprove) the hypothesis raised in this article but also contribute to the development of physiologically or even clinically useful mixtures of polyphenols with catechol structure in the future.

Published
2017

39. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

Author

Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Division of Hematology and Oncology, Alfred I. duPont Hospital for Children, Nemours Center for Childhood Cancer Research, Wilmington, Delaware ; Division of Hematology/Oncology, Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803., Division of Hematology and Oncology, Alfred I. duPont Hospital for Children, Nemours Center for Childhood Cancer Research, Wilmington, Delaware, Department of Pediatric Hematology/Oncology, Albert Einstein College of Medicine, Bronx, New York, Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, Division of Hematology and Oncology, Phoenix Children's Hospital, Phoenix, Arizona, Nationwide Children's Hospital and The Center for Childhood Cancer at The Research Institute, Columbus, Ohio, Kolb, E. Anders, Kamara, Davida, Zhang, Wendong, Lin, Juan, Hingorani, Pooja, Baker, Laurence, Houghton, Peter, Gorlick, Richard, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Division of Hematology and Oncology, Alfred I. duPont Hospital for Children, Nemours Center for Childhood Cancer Research, Wilmington, Delaware ; Division of Hematology/Oncology, Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803., Division of Hematology and Oncology, Alfred I. duPont Hospital for Children, Nemours Center for Childhood Cancer Research, Wilmington, Delaware, Department of Pediatric Hematology/Oncology, Albert Einstein College of Medicine, Bronx, New York, Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, Division of Hematology and Oncology, Phoenix Children's Hospital, Phoenix, Arizona, Nationwide Children's Hospital and The Center for Childhood Cancer at The Research Institute, Columbus, Ohio, Kolb, E. Anders, Kamara, Davida, Zhang, Wendong, Lin, Juan, Hingorani, Pooja, Baker, Laurence, Houghton, Peter, and Gorlick, Richard

Abstract

Background The combination of rapamycin and R1507, a fully human IgG1 monoclonal antibody targeting the IGF-1 receptor (IGF-1R), in osteosarcoma xenograft tumors in vivo is evaluated in this report. Procedure Six osteosarcoma xenograft tumor models were evaluated for growth inhibition after monotherapy with R1507, rapamycin, and the combination of both drugs. Phosphorylation of proteins involved in IGF-1R signaling is evaluated at various time points by immunoblotting. Results IGF-1R was expressed in five of the six human osteosarcoma tumor lines. Objective responses to R1507 were seen in four of the six tumor lines (OS1, OS2, OS9, and OS17) including one complete response in OS1. IGF-1R protein levels did not predict degree of response to R1507 in the sensitive tumors. However, in one of the two R1507-resistant tumors (OS33), there was a minimal expression of IGF-1R. An increase in AKT phosphorylation was observed in all the osteosarcoma tumors treated with rapamycin. However, phosphorylation of AKT was inhibited when rapamycin was used in combination with R1507. In three of the xenograft tumor lines, there was an improvement in response when R1507 was used in combination with rapamycin. Conclusions IGF-1R inhibition by R1507 induced tumor growth delays and improvement in event-free survival in four of six osteosarcoma xenograft tumor lines. R1507 negates increased signaling through AKT in response to mammalian target of rapamycin inhibition, suggesting that the combination is worthy of further evaluation in patients. As R1507 and other IGF-1R inhibitors advance in clinical trials, it will be important to understand biomarkers of response and pathways of resistance. Pediatr Blood Cancer 2010;55:67???75. ?? 2010 Wiley-Liss, Inc.

Published
2010

40. The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation

Author

Department of Hematology and Oncology, University of Regensburg Medical School, D-93053 Regensburg, Germany ; Department of Pediatrics, Division of Hematology and Oncology, Bone Marrow Transplantation Program, University of Michigan, Ann Arbor, 48109, Michigan ; Department of Hematology and Oncology, University of Regensburg Medical School, Franz-Josef-Strauß Allee 11, D-93053 Regensburg, Germany., Department of Pediatrics, Division of Hematology and Oncology, Bone Marrow Transplantation Program, University of Michigan, Ann Arbor, 48109, Michigan, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, 48109, Michigan, Department of Hematology and Oncology, University of Regensburg Medical School, D-93053 Regensburg, Germany, Hildebrandt, Gerhard C., Choi, Sung W., Mueller, Gunnar, Olkiewicz, Krystyna M., Moore, Bethany B., Cooke, Kenneth R., Department of Hematology and Oncology, University of Regensburg Medical School, D-93053 Regensburg, Germany ; Department of Pediatrics, Division of Hematology and Oncology, Bone Marrow Transplantation Program, University of Michigan, Ann Arbor, 48109, Michigan ; Department of Hematology and Oncology, University of Regensburg Medical School, Franz-Josef-Strauß Allee 11, D-93053 Regensburg, Germany., Department of Pediatrics, Division of Hematology and Oncology, Bone Marrow Transplantation Program, University of Michigan, Ann Arbor, 48109, Michigan, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, 48109, Michigan, Department of Hematology and Oncology, University of Regensburg Medical School, D-93053 Regensburg, Germany, Hildebrandt, Gerhard C., Choi, Sung W., Mueller, Gunnar, Olkiewicz, Krystyna M., Moore, Bethany B., and Cooke, Kenneth R.

Published
2008

41. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer Conflict of Interest: University of Michigan has filed a patent on TW-37, which has been licensed by Ascenta Therapeutics Inc. University of Michigan and Dr. Shaomeng Wang own equity in Ascenta. Dr. Shaomeng Wang also serves as a consultant for Ascenta and is the principal investigator on research contract from Ascenta to University of Michigan.

Author

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI ; Fax: +313-576-8389. ; Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R. Street, Detroit, MI 48201, Wang, Zhiwei, Song, Wen, Aboukameel, Amro, Mohammad, Mussop, Wang, Guoping, Banerjee, Sanjeev, Kong, Dejuan, Wang, Shaomeng, Sarkar, Fazlul H., Mohammad, Ramzi M., Department of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI ; Fax: +313-576-8389. ; Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R. Street, Detroit, MI 48201, Wang, Zhiwei, Song, Wen, Aboukameel, Amro, Mohammad, Mussop, Wang, Guoping, Banerjee, Sanjeev, Kong, Dejuan, Wang, Shaomeng, Sarkar, Fazlul H., and Mohammad, Ramzi M.

Abstract

Bcl-2 family of proteins plays critical roles in human cancers, including pancreatic cancer, suggesting that the discovery of specific agents targeting Bcl-2 family proteins would be extremely valuable for pancreatic cancer therapy. We have previously reported the synthesis and characterization of TW-37, which seems to be a negative regulator of Bcl-2. In this investigation, we tested our hypothesis whether TW-37 could be an effective inhibitor of cell growth, invasion and angiogenesis in pancreatic cancer cells. Using multiple cellular and molecular approaches such as MTT assay, apoptosis enzyme-linked immunosorbent assay, real-time reverse transcription-polymerase chain reaction, Western blotting, electrophoretic mobility shift assay for measuring DNA binding activity of NF-??B, migration, invasion and angiogenesis assays, we found that TW-37, in nanomolar concentrations, inhibited cell growth in a dose- and time-dependent manner. This was accompanied by increased apoptosis and concomitant attenuation of NF-??B, and downregulation of NF-??B downstream genes such as MMP-9 and VEGF , resulting in the inhibition of pancreatic cancer cell migration, invasion and angiogenesis in vitro and caused antitumor activity in vivo . From these results, we conclude that TW-37 is a potent inhibitor of progression of pancreatic cancer cells, which could be due to attenuation of Bcl-2 cellular signaling processes. Our findings provide evidence showing that TW-37 could act as a small-molecule Bcl-2 inhibitor on well-characterized pancreatic cancer cells in culture as well as when grown as tumor in a xenograft model. We also suggest that TW-37 could be further developed as a potential therapeutic agent for the treatment of pancreatic cancer. ?? 2008 Wiley-Liss, Inc.

Published
2008

42. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells

Author

Departments of Urology and Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 ; 7312 CCGC, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0946., Departments of Urology and Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, Loberg, Robert D., Tantivejkul, Kwanchanit, Craig, Matthew, Neeley, Chris K., Pienta, Kenneth J., Departments of Urology and Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 ; 7312 CCGC, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0946., Departments of Urology and Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, Loberg, Robert D., Tantivejkul, Kwanchanit, Craig, Matthew, Neeley, Chris K., and Pienta, Kenneth J.

Abstract

Patients with advanced prostate cancer often exhibit increased activation of the coagulation system. The key activator of the coagulation cascade is the serine protease thrombin which is capable of eliciting numerous cellular responses. We previously reported that the thrombin receptor PAR1 is overexpressed in prostate cancer. To investigate further the role of PAR1 in prostate cancer metastasis, we examined the effects of thrombin activation on cell adhesion and motility in PC-3 prostate cancer cells. Activation of PAR1-induced dynamic cytoskeletal reorganization and reduced PC-3 binding to collagen I, collagen IV, and laminin ( P < 0.01) but not fibronectin. Expression of the cell surface integrin receptors did not change as assessed by flow cytometry. Immunofluorescence microscopy revealed that PAR1 stimulation caused reorganization of the focal adhesions, suggesting that PAR1 activation in PC-3 cells may be modulating cell adhesion through integrin function but not expression. Furthermore, RhoA was activated upon stimulation with thrombin with subsequent cell contraction, decreased cell adhesion, and induced migration towards monocyte chemoattractant protein 1 (MCP-1; CCL2). Thus, it appears that thrombin stimulation plays a role in prostate cancer metastasis by decreasing cell adhesion to the extracellular matrix and positioning the cell in a “ready state” for migration in response to a chemotactic signal. Further exploration is needed to determine whether PAR1 activation affects other signaling pathways involved in prostate cancer. J. Cell. Biochem. 101:1292–1300, 2007. © 2007 Wiley-Liss, Inc.

Published
2007

43. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs

Author

From the Section of Gastroenterology and Hepatology, and Hematology and Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana; Chiron Corporation, Emeryville, California; Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, 48109, Ann Arbor, Michigan, From the Section of Gastroenterology and Hepatology, and Hematology and Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana; Chiron Corporation, Emeryville, California, Ann Arbor, Sanchez-Pescador, R., Leissinger, C., Lagier, R., Lok, A.S.F., Ghany, Marc G., From the Section of Gastroenterology and Hepatology, and Hematology and Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana; Chiron Corporation, Emeryville, California; Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, 48109, Ann Arbor, Michigan, From the Section of Gastroenterology and Hepatology, and Hematology and Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana; Chiron Corporation, Emeryville, California, Ann Arbor, Sanchez-Pescador, R., Leissinger, C., Lagier, R., Lok, A.S.F., and Ghany, Marc G.

Abstract

Chronic liver disease due to hepatitis C virus (HCV) infection is a major problem in hemophiliacs. Recent reports suggested that hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus (HIV) have an increased incidence of liver failure but the mechanism of accelerated liver injury is not clear. We tested plasma from 100 hemophiliacs for anti-HCV by second generation ELISA, anti-HIV by EIA, and HCV RNA and HIV RNA by branched DNA and polymerase chain reaction assays to determine if hemophiliacs coinfected with HCV and HIV have higher HCV RNA levels and more active liver disease. Seventy-nine (79%) patients were anti-HCV positive, of whom 85% were HCV RNA positive. None of the anti-HCV-negative patients had detectable HCV RNA in plasma. Forty-two (42%) patients were anti-HIV positive, of whom 47% had detectable HIV RNA. All the anti-HIV-positive patients were also anti-HCV positive. The prevalence of both anti-HCV and anti-HIV increased significantly with age. There was no difference in HCV RNA levels between anti-HIV-positive and anti-HIV-negative patients (mean: 21??4 vs 18??5 Meq/ml), although HCV RNA levels were significantly higher in anti-HIV-positive patients with CD4 counts<200/mm 3 (P =0.008). There was an inverse correlation between HCV RNA levels and CD4 counts but no correlation was found between HCV RNA and serum aminotransferase levels. We found a high prevalence of HCV and HIV coinfection in our hemophiliacs. Hepatitis C virus replication appears to be increased in patients with severe immunodeficiency secondary to progressive HIV infection. However, there was no correlation between HCV RNA and serum ALT level, suggesting that HCV is not directly cytopathic.

Published
2006

44. Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies

Author

Duhoux, François, Ameye, Geneviève, Lambot, Virginie, Herens, Christian, Labis, Elise, Terré, Christine, Nadal, Nathalie, Laibe, Sophy, Mozziconacci, Marie-Joëlle, Raynaud, Sophie, Wlodarska, Iwona, Michaux, Lucienne, Roche-Lestienne, Catherine, Libouton, Jeanne-Marie, Decottignies, Anabelle, Taviaux, Sylvie, Chapiro, Elise, Nguyen Khac, Florence, Struski, Stéphanie, Dobbelstein, Sophie, Dastugue, Nicole, Lippert, Eric, Speleman, Frank, Van Roy, Nadine, De Weer, An, Rack, Katrina, Talmant, Pascaline, Richebourg, Steven, Mugneret, Francine, Tigaud, Isabelle, Groupe Francophone de Cytogénétique Hématologique (GFCH), Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO), Lambert, Frédéric, Vikkula, Miikka, Poirel, Hélène, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, CHU de Liège - Center for Human Genetics, CHU de Nice - Center for Human Genetics, KULeuven - Center for Human Genetics, CHU de Lille - Center for Human Genetics, CHU de Montpellier - Center for Human Genetics, Groupe Hospitalier Pitié-Salpétrière - Center for Human Genetics, Hôpital Purpan, Toulouse - Center for Human Genetics, CHU de Bordeaux - Center for Human Genetics, UZ Ghent - Center for Human Genetics, IPG - Center for Human Genetics, CHU de Nantes - Center for Human Genetics, CHU de Dijon - Center for Human Genetics, Centre Hospitalier Lyon Sud - Center for Human Genetics, Institut Paoli-Calmettes - Center for Human Genetics, CHU Hôpital Nord, Saint-Etienne - Center for Human Genetics, Centre Hospitalier de Versailles - Center for Human Genetics, and UCL - SSS/DDUV - Institut de Duve

Subjects
Myeloid, Follicular lymphoma, lcsh:Medicine, Chromosomal translocation, CYTOGENETIC ANALYSIS, TUMOR-SUPPRESSOR GENE, Hematologic Cancers and Related Disorders, Chromosomal Disorders, Chromosome instability, hemic and lymphatic diseases, Molecular Cell Biology, lcsh:Science, In Situ Hybridization, Fluorescence, MYELODYSPLASTIC SYNDROME, Multidisciplinary, medicine.diagnostic_test, Chromosome Biology, NON-HODGKINS-LYMPHOMAS, Chromosomal Deletions and Duplications, Genomics, Hematology, Telomere, DNA-Binding Proteins, medicine.anatomical_structure, Oncology, Chromosomes, Human, Pair 1, Hematologic Neoplasms, Cytogenetic Analysis, Medicine, Research Article, medicine.medical_specialty, Chromosome Structure and Function, Biology, Polymorphism, Single Nucleotide, Cell Line, Cytogenetics, CHROMOSOMAL TRANSLOCATIONS, Complex Karyotype, medicine, Genetics, Cancer Genetics, Humans, Clinical Genetics, Chromosome Aberrations, CHRONIC LYMPHOCYTIC-LEUKEMIA, Breakpoint, lcsh:R, Biology and Life Sciences, Cancers and Neoplasms, Human Genetics, IN-SITU HYBRIDIZATION, medicine.disease, Molecular biology, COPY NUMBER, NEUROBLASTOMA, lcsh:Q, FOLLICULAR LYMPHOMA, Fluorescence in situ hybridization, Transcription Factors
Abstract

Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mainly observed in myeloid disorders; and unbalanced non-telomeric rearrangements (N = 39), mainly observed in lymphoid proliferations and frequently associated with a highly complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36 were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas [follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or result from chromosomal instability during oncogenesis.

Published
2011

46. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies

Author

UCL - SSS/IREC - Institut de recherche expérimentale et clinique, CHU de Liège - Center for Human Genetics, CHU de Nice - Center for Human Genetics, KULeuven - Center for Human Genetics, CHU de Lille - Center for Human Genetics, CHU de Montpellier - Center for Human Genetics, Groupe Hospitalier Pitié-Salpétrière - Center for Human Genetics, Hôpital Purpan, Toulouse - Center for Human Genetics, CHU de Bordeaux - Center for Human Genetics, UZ Ghent - Center for Human Genetics, IPG - Center for Human Genetics, CHU de Nantes - Center for Human Genetics, CHU de Dijon - Center for Human Genetics, Centre Hospitalier Lyon Sud - Center for Human Genetics, Institut Paoli-Calmettes - Center for Human Genetics, CHU Hôpital Nord, Saint-Etienne - Center for Human Genetics, Centre Hospitalier de Versailles - Center for Human Genetics, UCL - SSS/DDUV - Institut de Duve, Duhoux, François, Ameye, Geneviève, Lambot, Virginie, Herens, Christian, Labis, Elise, Terré, Christine, Nadal, Nathalie, Laibe, Sophy, Mozziconacci, Marie-Joëlle, Raynaud, Sophie, Wlodarska, Iwona, Michaux, Lucienne, Roche-Lestienne, Catherine, Libouton, Jeanne-Marie, Decottignies, Anabelle, Taviaux, Sylvie, Chapiro, Elise, Nguyen Khac, Florence, Struski, Stéphanie, Dobbelstein, Sophie, Dastugue, Nicole, Lippert, Eric, Speleman, Frank, Van Roy, Nadine, De Weer, An, Rack, Katrina, Talmant, Pascaline, Richebourg, Steven, Mugneret, Francine, Tigaud, Isabelle, Groupe Francophone de Cytogénétique Hématologique (GFCH), Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO), Lambert, Frédéric, Vikkula, Miikka, Poirel, Hélène, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, CHU de Liège - Center for Human Genetics, CHU de Nice - Center for Human Genetics, KULeuven - Center for Human Genetics, CHU de Lille - Center for Human Genetics, CHU de Montpellier - Center for Human Genetics, Groupe Hospitalier Pitié-Salpétrière - Center for Human Genetics, Hôpital Purpan, Toulouse - Center for Human Genetics, CHU de Bordeaux - Center for Human Genetics, UZ Ghent - Center for Human Genetics, IPG - Center for Human Genetics, CHU de Nantes - Center for Human Genetics, CHU de Dijon - Center for Human Genetics, Centre Hospitalier Lyon Sud - Center for Human Genetics, Institut Paoli-Calmettes - Center for Human Genetics, CHU Hôpital Nord, Saint-Etienne - Center for Human Genetics, Centre Hospitalier de Versailles - Center for Human Genetics, UCL - SSS/DDUV - Institut de Duve, Duhoux, François, Ameye, Geneviève, Lambot, Virginie, Herens, Christian, Labis, Elise, Terré, Christine, Nadal, Nathalie, Laibe, Sophy, Mozziconacci, Marie-Joëlle, Raynaud, Sophie, Wlodarska, Iwona, Michaux, Lucienne, Roche-Lestienne, Catherine, Libouton, Jeanne-Marie, Decottignies, Anabelle, Taviaux, Sylvie, Chapiro, Elise, Nguyen Khac, Florence, Struski, Stéphanie, Dobbelstein, Sophie, Dastugue, Nicole, Lippert, Eric, Speleman, Frank, Van Roy, Nadine, De Weer, An, Rack, Katrina, Talmant, Pascaline, Richebourg, Steven, Mugneret, Francine, Tigaud, Isabelle, Groupe Francophone de Cytogénétique Hématologique (GFCH), Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO), Lambert, Frédéric, Vikkula, Miikka, and Poirel, Hélène

Abstract

Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mainly observed in myeloid disorders; and unbalanced non-telomeric rearrangements (N = 39), mainly observed in lymphoid proliferations and frequently associated with a highly complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36 were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas [follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or result from chromosomal instability during oncogenesis.

Published
2011

47. Racial differences in cervical cancer survival in the Detroit metropolitan area

Author

Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, Department of Internal Medicine, Mclaren Regional Medical Center, Michigan State University, Flint, Michigan, Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan ; Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan ; Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan ; Fax: (313) 576-8764 ; Barbara Ann Karmanos Cancer Institute, 4100 John R, Room 4221 Hudson Webber Cancer Research Building, Detroit, MI 48202, Movva, Sujana, Noone, Anne-Michelle, Banerjee, Mousumi, Patel, Divya A., Schwartz, Kendra, Yee, Cecilia L., Simon, Michael S., Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, Department of Internal Medicine, Mclaren Regional Medical Center, Michigan State University, Flint, Michigan, Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan ; Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, Population Studies and Prevention Program, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan ; Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan ; Fax: (313) 576-8764 ; Barbara Ann Karmanos Cancer Institute, 4100 John R, Room 4221 Hudson Webber Cancer Research Building, Detroit, MI 48202, Movva, Sujana, Noone, Anne-Michelle, Banerjee, Mousumi, Patel, Divya A., Schwartz, Kendra, Yee, Cecilia L., and Simon, Michael S.

Abstract

BACKGROUND African-American (AA) women have lower survival rates from cervical cancer compared with white women. The objective of this study was to examine the influence of socioeconomic status (SES) and other variables on racial disparities in overall survival among women with invasive cervical cancer. METHODS One thousand thirty-six women (705 white women and 331 AA women) who were diagnosed with primary invasive cancer of the cervix between 1988 and 1992 were identified through the Metropolitan Detroit Cancer Surveillance System (MDCSS), a registry in the Surveillance, Epidemiology, and End Results (SEER) database. Pathology, treatment, and survival data were obtained through SEER. SES was categorized by using occupation, poverty, and educational status at the census tract level. Cox proportional hazards models were used to compare overall survival between AA women and white women adjusting for sociodemographics, clinical presentation, and treatment. RESULTS AA women were more likely to present at an older age ( P < .001), with later stage disease ( P < .001), and with squamous histology ( P = .01), and they were more likely to reside in a census tract categorized as Working Poor (WP) ( P < .001). After multivariate adjustment, race no longer had a significant impact on survival. Women who resided in a WP census tract had a higher risk of death than women from a Professional census tract ( P = .05). There was a significant interaction between disease stage and time with the effect of stage on survival attenuated after 6 years. CONCLUSIONS In this study, factors that affected access to medical care appeared to have a more important influence than race on the long-term survival of women with invasive cervical cancer. Cancer 2008. © 2008 American Cancer Society.

Published
2008

48. Obesity and mortality in men with locally advanced prostate cancer

Author

Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, Department of Radiation Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts ; Fax: (617) 726-4899. ; Massachusetts General Hospital, Yawkey 7038, 55 Fruit St., Boston, MA 02114, Efstathiou, Jason A., Bae, Kyounghwa, Shipley, William U., Hanks, Gerald E., Pilepich, Miljenko V., Sandler, Howard M., Smith, Matthew R., Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, Department of Radiation Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts ; Fax: (617) 726-4899. ; Massachusetts General Hospital, Yawkey 7038, 55 Fruit St., Boston, MA 02114, Efstathiou, Jason A., Bae, Kyounghwa, Shipley, William U., Hanks, Gerald E., Pilepich, Miljenko V., Sandler, Howard M., and Smith, Matthew R.

Abstract

BACKGROUND. Greater body mass index (BMI) is associated with shorter time to prostate-specific antigen (PSA) failure following radical prostatectomy and radiation therapy (RT). Whether BMI is associated with prostate cancer-specific mortality (PCSM) was investigated in a large randomized trial of men treated with RT and androgen deprivation therapy (ADT) for locally advanced prostate cancer. METHODS. Between 1987 and 1992, 945 eligible men with locally advanced prostate cancer were enrolled in a phase 3 trial (RTOG 85-31) and randomized to RT and immediate goserelin or RT alone followed by goserelin at recurrence. Height and weight data were available at baseline for 788 (83%) subjects. Cox regression analyses were performed to evaluate the relations between BMI and all-cause mortality, PCSM, and nonprostate cancer mortality. Covariates included age, race, treatment arm, history of prostatectomy, nodal involvement, Gleason score, clinical stage, and BMI. RESULTS. The 5-year PCSM rate for men with BMI <25 kg/m 2 was 6.5%, compared with 13.1% and 12.2% in men with BMI ≥25 to <30 and BMI ≥30, respectively (Gray's P = .005). In multivariate analyses, greater BMI was significantly associated with higher PCSM (for BMI ≥25 to <30, hazard ratio [HR] 1.52, 95% confidence interval [CI], 1.02–2.27, P = .04; for BMI ≥30, HR 1.64, 95% CI, 1.01–2.66, P = .04). BMI was not associated with nonprostate cancer or all-cause mortality. CONCLUSIONS. Greater baseline BMI is independently associated with higher PCSM in men with locally advanced prostate cancer. Further studies are warranted to evaluate the mechanism(s) for increased cancer-specific mortality and to assess whether weight loss after prostate cancer diagnosis alters disease course. Cancer 2007. © 2007 American Cancer Society.

Published
2008

49. A novel role for notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes

Author

Departments of Hematology and Oncology, Mie University School of Medicine, Departments of Laboratory Medicine, Mie University School of Medicine, Blood Transfusion Service, Mie University Hospital, Tenri Institute of Medical Research, Departments of Bioregulation, Mie University School of Medicine, Hoshino, Natsuki, Katayama, Naoyuki, Shibasaki, Tetsunori, Ohishi, Kohshi, Nishioka, Junji, Masuya, Masahiro, Miyahara, Yoshihiro, Hayashida, Masahiko, Shimomura, Daiki, Kato, Takuma, Nakatani, Kaname, Nishii, Kazuhiro, Kuribayashi, Kagemasa, Nobori, Tsutomu, Shiku, Hiroshi, Departments of Hematology and Oncology, Mie University School of Medicine, Departments of Laboratory Medicine, Mie University School of Medicine, Blood Transfusion Service, Mie University Hospital, Tenri Institute of Medical Research, Departments of Bioregulation, Mie University School of Medicine, Hoshino, Natsuki, Katayama, Naoyuki, Shibasaki, Tetsunori, Ohishi, Kohshi, Nishioka, Junji, Masuya, Masahiro, Miyahara, Yoshihiro, Hayashida, Masahiko, Shimomura, Daiki, Kato, Takuma, Nakatani, Kaname, Nishii, Kazuhiro, Kuribayashi, Kagemasa, Nobori, Tsutomu, and Shiku, Hiroshi

Abstract

Human Langerhans cells (LCs) are of hematopoietic origin, but cytokine regulation of their development is not fully understood. Notch ligand Delta-1 is expressed in a proportion of the skin. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor-ß1 (TGF-ß1) are also secreted in the skin. We report here that Delta-1, in concert with GM-CSF and TGF-ß1, induces the differentiation of human CD14+ blood monocytes into cells that express LC markers: CD1a, Langerin, cutaneous lymphocyte-associated antigen, CC chemokine receptor 6, E-cadherin, and Birbeck granules. The resulting cells display phagocytic activity and chemotaxis to macrophage inflammatory protein-1 (MIP-1). In response to CD40 ligand and tumor necrosis factor , the cells acquire a mature phenotype of dendritic cells that is characterized by up-regulation of human leukocyte antigen (HLA)-ABC, HLA-DR, CD80, CD86, CD40, and CD54 and appearance of CD83. These cells in turn show chemotaxis toward MIP-1ß and elicit activation of CD8+ T cells and T helper cell type 1 polarization of CD4+ T cells. Thus, blood monocytes can give rise to LCs upon exposure to the skin cytokine environment consisting of Delta-1, GM-CSF, and TGF-ß1, which may be, in part, relevant to the development of human epidermal LCs. Our results extend the functional scope of Notch ligand -1 in human hematopoiesis.

Published
2007

50. Recommendations for the use of long-term central venous catheter (CVC) in children with hemato-oncological disorders: management of CVC-related occlusion and CVC-related thrombosis. On behalf of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP).

Author

Giordano, Paola, Saracco, Paola, Grassi, Massimo, Luciani, Matteo, Banov, Laura, Carraro, Francesca, Crocoli, Alessandro, Cesaro, Simone, Zanazzo, Giulio, Molinari, Angelo, Zanazzo, Giulio Andrea, Molinari, Angelo Claudio, and Italian Association of Pediatric Hematology and Oncology (AIEOP)

Subjects
HEMATOLOGIC malignancies, CENTRAL venous catheterization, CHILDHOOD cancer, THROMBOSIS, BLOOD coagulation
Abstract

Central venous catheters (CVC), used for the management of children with hemato-oncological disorders, are burdened by a significant incidence of mechanical, infective, or thrombotic complications. These complications favor an increasing risk in prolongation of hospitalization, extra costs of care, and sometimes severe life-threatening events. No guidelines for the management of CVC-related occlusion and CVC-related thrombosis are available for children. To this aim, members of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP) reviewed the pediatric and adult literature to propose the first recommendations for the management of CVC-related occlusion and CVC-related thrombosis in children with hemato-oncological disorders. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results